1. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma
   Zhong-liu Wei et al, 2022, BMC Gastroenterology CrossRef
2. Structural basis of CDK3 activation by cyclin E1 and inhibition by dinaciclib
   Wenjun Gui et al, 2023, Biochemical and Biophysical Research Communications CrossRef
3. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
   Brilliant N. Marak et al, 2020, European Journal of Medicinal Chemistry CrossRef
4. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer
   Lufeng Zheng et al, 2016, Molecular and Cellular Endocrinology CrossRef
5. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
   Xiumei Zhang et al, 2019, PLOS ONE CrossRef
6. Cdk3-promoted epithelial-mesenchymal transition through activating AP-1 is involved in colorectal cancer metastasis
   Jinping Lu et al, 2016, Oncotarget CrossRef
7. CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway
   Ting Cao et al, 2017, Oncotarget CrossRef
8. EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4
   Hongfeng Li et al, 2023, Hereditas CrossRef
9. Circular RNA Controls Tumor Occurrence and Development via Cell Cycle Regulation
   Fang Liu et al, 2022, OncoTargets and Therapy CrossRef
10. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
    J Cui et al, 2015, Oncogene CrossRef
11. Upregulation of LINC00319 indicates a poor prognosis and promotes cell proliferation and invasion in cutaneous squamous cell carcinoma
    Fumin Li et al, 2018, Journal of Cellular Biochemistry CrossRef
12. An overview of CDK3 in cancer: clinical significance and pharmacological implications
    Theodosia Teo et al, 2022, Pharmacological Research CrossRef